Рак молочної залози (стр. 34 )

136 Cancer Care Ontaria. Breast Cancer Disease Site Group. Vinorelbine in stage IV breast cancer, Toronta;Cancer Care Ontario:2003. (Evidence Summary #1^f). [cited on 12 July 2005]. Available from URL: http:// www. cancercare. on. ca/pd</pebceslJtf. pdf

137 Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M et al. Randomized comparison of vinorelbine and melphalan in anthracyctine-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567-74.

138 Venturino A, Comandini D, Simoni C, Merlini L, Naso C, Palurnbo R, et al. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leueovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. Breast Cancer Res Treat 2000;60:195-200

139 Norris B, Pritehard Kl, James K, Myles J, Bennett K, Marlin S, etal. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MAS. J Clin Oncol 2000;18:2385-94.

140 Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Cone/o E, Ackland S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 20Q2;86:1367-72.

141 Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999,17:485-93.

142 OshaughnessyJA, BlumJ, Moiseyenko V, Jones SE, Miles D, Bell D, etal. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF fcyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-54.

143 O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V. Ayoub JP, Cervantes G, et perior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.

144 Pavlakis N, Stockier M. Bisphosphonates for breast cancer (Cochrane Review). In: The Ccchrane Library, Issue 2, 2002. Oxford: Update Software. 2002.

145 Powles T, Paterson S, Kanis f A, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodranate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24.

146 Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients wrth multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16(3): 1218-25.

147 Cancer Care Ontaria. Breast Cancer Disease Site Group. Adjuvant systemic therapy for node-negative breast cancer. Toronto, Cancer Care Ontaria:2002. (Practice Guideline Report #1-8). [cited 12 July 2005).

148 Rosen LS, Gordon DH, Dugan WJ/, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least: one osteolytic lesion. Cancer. 2004; 100(11:36-43,

149 Love RR, Due NB, Allred DC, Binh NC, Dinh NV, Kha NN, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clirt Oncol 2002; 20:2559-66,

150 Tamoxifen for early breast cancer: an overview of the randomised trials. Early BreastCancer Trialists'CollaborativeGroup. Lancet 1998:351(9114): 1451-67.

151 Anonymous, Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet. 1993;341 (8856): 1293-8.

152 Kaufmann M, Jonat W, Blarney R, Cuzick J, Namer M. Fogelman I, et rvival analyses from the ZEBRA study, goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003;39(12):1711-7.

153 Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauemhofer T, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20(24):4621-7.

154 Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of bined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer a meta-analysis of four randomized trials. J Clin Oncol. 2001; 19(2):343-53.

155 Gardner FJ, Konje JC, Abrams KR. Brown LJ, Khanna S. AI-Azzawi F, et al. Endometrial protection from tarnoxifen-stimulatedchanges by a levonorgestrel-releasing irrtrauterine system: a randomised controlled trial. Lancet. 2QOD;356(9243):1711-7.

156 Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausa} women with early breast cancer first results of the AT AC randomised trial. Lancet. 2002 ;359(9324):2131-9,

157 Goss PE, Ingle JN, Martino S. Robert NJ, Muss HB, Piccart MJ, et al Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTGMA.17.J Natl Cancer Inst. 2005;97(17):1262-71.

158 Eiermann W, Paepke S, Appfelstaedt), Llombart-Cussac A, Eremin J, Vinholes j, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-32.

159 Recht A, Come SE, Henderson 1C, Gelman RS. Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl j Med. 1996;334(21):1356^1.

160 Colleoni M, Bonetti M, Coafes AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000; 18(31:584-90.

161 Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol. 2003:21 (20):3792-

162 Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, etal. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13(6): 883-8.

163 Col NF, Hirota UCOrrRK. Hormonereplacementtherapyafterbreastcancer: 3 systemic review and quantative assessment of risk. J Clin Oncol 2001; 19:2357-63.

164 Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-27.

165 Pritehard, K. I., Khan, H., Levins, M. Steering Committee on Clinical Practice Guidelines for the care and treatment of breast cancer. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ 2002. 16; 166(8): 1017-22.

166 Ambler N, Rumsey N, Harcourt D, Khan F, Cawthom S, Barker J Specialist nurse counsellor interventions at the time of diagnosis of breast cancer: comparing 'advocacy' with a conventional approach. I Adv Nurs. 1999;29(2):445-53.

167 Liebert B, Parle M, Roberts C, Redman S, Carrick 5, Gallagher J, et al. An evidence-based specialist breast nurse role in practice: a multicentre implementation study. Eur J Cancer Care (Engt) 2003;120):91-7.

168 Royal College of Nursing. A framework tor adult cancer nursing. London;TheColIege:2003. [cited 12 July 2005] Available from URL:: http:// www. rcn. org. uk/mernbers/downloads/RCNCancerFrameworkAug2QQ3. pdf

169 Maguire GP, Lee EC, Bevington D), Kuchemann CS, Crabtree RJ, Cornel! CE. Psychiatric problems in the first year after mastectomy. BMJ 1978;1.963-5.

170 Irvine RN, Brown 8, Crooks D, Roberts J, Browne C. Psychosocial adjustment in women with breast cancer. Cancer 1991 ;67:1097-117.

171 Kissane DW, Clarke DM. Ikm J, Bloch S, Smith GC. Vitetta L, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. Med J Aust 1998;169(4):192-6.

172 National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Guidelines for Supportive Care. Distress Management. [cited 28 September 2005].

Available from uri: http://www-nccn. org/ professionals/physician^gls/PDF/distress. pdf

173 Australia. National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown;National Breast Cancer Centre:2D03.

174 Morasso G, Costantini M, Viterbori P, Bonci F, Del Mastro L, Musso M, et al. Predicting mciod disorders in breast cancer patientS-Eur) Cane 2001:37: 216-23.

175 McLachlan SA, Devins GM, Goodwin PJ. Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in Breast cancer patients. EurJCancer 1998;34(4):510-7

176 Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. BMJ 2001;322(72B3):406-9.

177 Love AW, Kissane DW, Blcch S, Clarke D. Diagnostic efficiency of the Hospital Anxiety and Depression Scale in Women with early stage breast cancer Aust N Z J Psychiatry 2Q02;36:246-50.

178 Classen C, Butler LD, Koopman C, Miller E, DiMiceli S, Giese-Davis J, pportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial. Arch Gen Psychiatry 2001;58(5):494-501.